KWON, YONG TAE,权 容兑,權 容兌,JI, CHANG HOON,池昌勋,池昌勛,GANIPISETTI, SRINIVASRAO,喇 悟,KIM, HEE YEON,金希姸,MUN, SU RAN,文修兰,文修蘭,JUNG, CHAN HOON,郑灿勳,鄭燦勳,JUNG, EUI JUNG,郑宜静,鄭宜靜,SUNG, KI WOON,成基云
申请号：
TW108126236
公开号：
TW202021947A
申请日:
2019.07.24
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.本發明有關一種其中一新的p62配位體與一標靶結合配位體由一連接子連接之新穎的AUTOTAC嵌合化合物、其立體異構物、水合物、溶劑合物或前驅藥，及一種包含其作為活性成份，用於通過降解標靶蛋白質來預防或治療疾病的藥學或食品組合物。其等可靶定特定蛋白質以調整他們的濃度，亦可將藥物及其它小分子化合物遞送至溶酶體。根據本發明之AUTOTAC嵌合化合物可有效地作為用於通過選擇性消除特定蛋白質來預防、改善或治療各種疾病的藥學組成物。
